Park Medi World Ltd
NSE: PARKHOSPS BSE: 544645
Park Medi World engaged in the business of, inter alia, establishing, maintaining and running hospitals, nursing homes, clinics, dispensaries, maternity homes, child welfare, family planning etc.(Source : 202503 Annual Report Page No:320)
₹241
52W: ₹138 — ₹267
PE 284 · Book ₹19.9 · +1111% vs bookMarket Cap₹10,407 Cr
Stock P/E284Price to Earnings
ROCE10.1%Return on Capital
ROE7.52%Return on Equity
Div. Yield0%Face Value ₹2
Strengths
- +Company has reduced debt.
- +Company is almost debt free.
Weaknesses
- −Stock is trading at 12.2 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has a low return on equity of 7.32% over last 3 years.
- −Company's cost of borrowing seems high
- −Working capital days have increased from -53.1 days to 596 days
Shareholding Pattern
Promoters82.89%
FIIs0.86%
DIIs8.95%
Public6.98%
| Category | Dec 2025 | Mar 2026 |
|---|---|---|
| Promoters | 82.89% | 82.89% |
| FIIs | 1.28% | 0.86%▼0.4 |
| DIIs | 8.58% | 8.95%▲0.4 |
| Public | 7.06% | 6.98%▼0.1 |
Financial Statements
| Metric | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 22.76 | 23.26 | 32.69 | 45.87 | 27.43 |
| Expenses | 18.09 | 15.37 | 17.39 | 27.85 | 22.66 |
| Operating Profit | 4.67 | 7.89 | 15.3 | 18.02 | 4.77 |
| OPM % | 20.52% | 33.92% | 46.8% | 39.28% | 17.39% |
| Net Profit | 0.18 | 3.48 | 8.55 | 14.56 | 8.61 |
| EPS ₹ | 0.01 | 0.09 | 0.22 | 0.34 | 0.2 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹129Cr, up 40.2% YoY. OPM at 41%.
Debt Position
Borrowings at ₹19Cr. Debt-to-equity ratio: 0.02x. Healthy balance sheet.
Capex Cycle
CWIP at ₹106Cr (149% of fixed assets). Significant capex underway — growth runway building.
Margin & Efficiency
ROCE improving from 0% (Mar 2022) to 10% (Mar 2026). Working capital days: 596.
Valuation
PE 284x with 10.1% ROCE. Price is 1111% above book value of ₹19.9. Dividend yield: 0%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Monitoring Agency Report 2d - CRISIL monitoring report for Q4 FY26 IPO proceeds; Rs 7,023.02 million utilized, Rs 676.98 million unutilized.
- Key Performance Indicators 2d - Company uploaded Key Performance Indicators from December 12, 2025 prospectus on its website.
- Announcement under Regulation 30 (LODR)-Change in Management 2d - Board approved cost, internal and secretarial auditor appointments on May 15, 2026.
- Board Meeting Outcome for Outcome Of Board Meeting Held On May 15 2026 2d - Board approved cost, internal and secretarial auditor appointments on May 15, 2026.
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 2d - FY26 revenue ₹1,679 crore, EBITDA ₹444 crore, PAT ₹274 crore; beds rose to 3,610, Panchkula commissioned.
- Rating update 4 Nov 2025 from crisil
- Rating update 24 Oct 2025 from crisil
- Transcript